Given that sFgl2 is readily detected, our results, together with previous findings (18), support the notion that Fgl2, especially sFgl2, may serve as a valuable and convenient biomarker for continuous monitoring of IBD progression and response to treatment in both animal research and clinical application. The gene discussed is FGL2; the disease is inflammatory bowel disease.